Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan in Pediatric ADPKD
NCT02964273Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2016
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) (4 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Change From Baseline in Spot Urine Osmolality (Pre-morning Dose) at Week 1 and Change From Baseline in Specific Gravity (Pre-morning Dose) at Week 1. Started Sep 2016; status: completed.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT02964273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02964273.